Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Ondine Biomedical, Inc. ( (GB:OBI) ) just unveiled an announcement.
Ondine Biomedical Inc. announced a US$4 million equity investment from hInsight-NX, a subsidiary of HCA Healthcare, Inc. This investment involves issuing new common shares, representing approximately 8.6041% of the company’s enlarged share capital. The funds will support Ondine’s strategic objectives, extending its cash runway into early Q4 2025. This investment underscores Ondine’s commitment to advancing its light-activated antimicrobial technologies and could enhance its market positioning by bolstering its financial stability. The completion of a previously announced private placement is still pending due to the investor’s personal circumstances.
More about Ondine Biomedical, Inc.
Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, known as photodisinfection. The company has a strong pipeline of investigational products using its proprietary technology, including a nasal photodisinfection system approved in several countries under the name Steriwave®. It is also developing treatments for various medical indications such as chronic sinusitis and ventilator-associated pneumonia.
YTD Price Performance: 45.71%
Average Trading Volume: 505,829
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £51.51M
For an in-depth examination of OBI stock, go to TipRanks’ Stock Analysis page.
